Recent Pfizer Press Releases

  • 8/18/14 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced it has completed the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for palbociclib. This NDA requests FDA approval of palbociclib, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have not received previous systemicmore...
  • 8/14/14 5:01 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bivalent recombinant LP2086 (rLP2086), the company’s vaccine candidate for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 through 25 year olds. The FDA has also granted Priority Review designation for the BLA, providing an anticipatedmore...
  • 8/13/14 5:42 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein])PCV13) for routine use to help protect adults aged 65 years and older against pneumococcal disease, which includes pneumonia caused by the 13 pneumococcal serotypes included in the vaccine.more...
  • 8/12/14 5:01 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today top-line results from two placebo-controlled studies conducted in China with Lyrica® (pregabalin) in patients with postherpetic neuralgia (pain after shingles or PHN) and painful diabetic peripheral neuropathy (pDPN), respectively. The PHN Phase 4 study, A0081276, met its primary endpoint by demonstrating a statistically significant reduction in pain when compared to placebo. Separately, the pDPN Phase 3more...
  • 8/7/14 8:00 am EDT

    Application Includes Data from Pfizer’s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the European Medicines Agency (EMA) has accepted Pfizer’s application seeking to expand the indication for Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults to include the prevention of pneumonia caused by the 13 pneumococcal serotypes contained in the vaccine. “Pneumococcal pneumonia continues to be a serious health problem, causingmore...
  • 8/4/14 8:00 am EDT

    Join Rascal Flatts Today and Choose Nexium 24HR - Satisfaction Guaranteed

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the members of Rascal Flatts, the most-awarded country music band of the past decade, are among the thousands of people who choose Nexium® 24HR every day since becoming available without a prescription for frequent heartburn this past May. Pfizer wants all frequent heartburn sufferers to experience Nexium Level ProtectionTM where they are provided access to the #1 doctor-prescribedmore...
  • 7/30/14 8:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has entered into a definitive agreement to acquire Baxter International Inc.’s portfolio of marketed vaccines for $635 million. As part of the transaction, Pfizer will also acquire a portion of Baxter’s facility in Orth, Austria, where these vaccines are manufactured. Baxter’s portfolio of marketed vaccines consists of NeisVac-C and FSME-IMMUN/TicoVac. NeisVac-C is a vaccine that helps protect againstmore...
  • 7/29/14 7:00 am EDT
    • Second-Quarter 2014 Reported Revenues(1) of $12.8 Billion
    • Second-Quarter 2014 Adjusted Diluted EPS(2) of $0.58, Reported Diluted EPS(1) of $0.45
    • Repurchased $2.9 Billion of Common Stock to Date in 2014
    • Reaffirmed 2014 Adjusted Diluted EPS(2) Guidance; Updated Certain Other 2014 Financial Guidance Components
    • Expects to Complete U.S. Regulatory Submission for Palbociclib in Advanced Breast Cancer in August 2014
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) reported financial results for second-quarter 2014. At the beginning of fiscal year 2014, the company began managing its commercial operations through a new global commercial structure consisting of three operating segments: the Global Innovative Pharmaceutical segment (GIP)(3); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC)(3); and the Global Established Pharmaceutical segment (GEP)(3).more...
  • 7/16/14 10:00 am EDT

    Pfizer’s Get Old Campaign Challenges Conventional Attitudes about Aging

    New social study finds 4.2 million tweets a year on aging; topic of health grew 48% in 2014 over 20132

    NEW YORK--(BUSINESS WIRE)--Life expectancy continues to climb — up to more than 81 years for women and 76 years for men3 – but many of us have concerns around aging. Pfizer is challenging Americans to address their #FOGO – Fear of Getting Old – as the next phase of Get Old, an initiative by Pfizer around aging, encouraging honest conversations and celebrating getting “old” at whatever stage of life you are. “We want people to Get Old with a new attitude. If youmore...
  • 7/16/14 9:26 am EDT

    InnoPharma Has Established Track Record in the Development of Hard-to-Make, Differentiated, Sterile Injectable Products


    Portfolio of 10 Approved Products and Pipeline of More Than 30 Products in Development; 19 Pending Approval with the United States Food and Drug Administration

    NEW YORK and PISCATAWAY, N.J.--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and InnoPharma, Inc., a privately held pharmaceutical development company, today announced that they have entered into an agreement under which Pfizer will acquire InnoPharma. Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments. InnoPharma’s current portfolio includes 10 generic productsmore...